[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Graham et al., 1997 - Google Patents

Agouti protein inhibits the production of eumelanin and phaeomelanin in the presence and absence of α‐melanocyte stimulating hormone

Graham et al., 1997

Document ID
13312492996978448747
Author
Graham A
Wakamatsu K
Hunt G
Ito S
Thody A
Publication year
Publication venue
Pigment cell research

External Links

Snippet

Melanocytes synthesise two types of melanin: the brown‐black eumelanin and the red‐ yellow phaeomelanin. In mice, the relative proportions of these two melanins are regulated by α‐MSH, which preferentially increases the synthesis of eumelanin and by the Agouti …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00—Cosmetic or similar toilet preparations
    • A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
    • A61K8/30—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Similar Documents

Publication Publication Date Title
Graham et al. Agouti protein inhibits the production of eumelanin and phaeomelanin in the presence and absence of α‐melanocyte stimulating hormone
Eves et al. α-Melanocyte stimulating hormone, inflammation and human melanoma
Swope et al. Defining MC1R regulation in human melanocytes by its agonist α-melanocortin and antagonists agouti signaling protein and β-defensin 3
Slominski et al. Functional activity of serotoninergic and melatoninergic systems expressed in the skin
Hida et al. Agouti protein, mahogunin, and attractin in pheomelanogenesis and melanoblast‐like alteration of melanocytes: a cAMP‐independent pathway
Suzuki et al. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis
Kim et al. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro
Abdel‐malek et al. The melanocortin‐1 receptor and human pigmentation
Cerdá-Reverter et al. Fish melanocortin system
Holder et al. Structure− activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors: part 2 modifications at the Phe position
Hearing The regulation of melanin formation
EP2659004B1 (en) Modulation of dynein in skin
US10054582B2 (en) Compositions and methods for inhibiting HMGB1 activation of melanocytes
CA2892134C (en) Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor
Ping et al. Activation of neurokinin-1 receptor by substance P inhibits melanogenesis in B16-F10 melanoma cells
Dong et al. Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A–dependent mechanism
Suzuki et al. Melanogenic effect of dersimelagon (MT‐7117), a novel oral melanocortin 1 receptor agonist
Koikov et al. Development of hMC1R selective small agonists for sunless tanning and prevention of genotoxicity of UV in melanocytes
Zbytek et al. Characterization of a ultraviolet B-induced corticotropin-releasing hormone-proopiomelanocortin system in human melanocytes
Buffey et al. Calcium plays a complex role in the regulation of melanogenesis in murine B16 melanoma cells
Beaumont et al. The melanocortin‐1 receptor gene polymorphism and association with human skin cancer
Kuo et al. N-(4-bromophenethyl) caffeamide inhibits melanogenesis by regulating AKT/glycogen synthase kinase 3 beta/microphthalmia-associated transcription factor and tyrosinase-related protein 1/tyrosinase
KR20140012274A (en) Agent for skin whitening comprising liver x receptor agonist
Chen et al. Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway
Kim et al. Targeting phosphorylation circuits on CREB and CRTCs as the strategy to prevent acquired skin hyperpigmentation